Steven Pincus, PhD

Steven obtained his B.S. and Ph.D. in Biochemistry from the State University of NY, Buffalo. His Ph.D. thesis project involved studies on the mechanism of Adenovirus DNA replication. He obtained his post-doctoral training in microbiology at the State University of NY, Stony Brook under an NIH Fellowship studying inhibitors of picornavirus replication. He then joined Virogenetics where he was Senior Scientist in Molecular Biology and Microbiology. Here he was involved in the development of highly attenuated poxvirus vaccine vectors and developed vaccine candidates for Measles, Flaviviruses, Human Cytomegalovirus and therapeutic vaccines against several cancers along with release assays. At Elusys Therapeutics he was Senior Director Virology and Animal Biology. He then joined Novavax, Inc., focusing on the development of vaccines against Influenza and Respiratory Syncytial Virus, based on Virus-Like Particle produced using a baculovirus expression system and insect cells. He was a key member of the team that secured a contract award valued at up to $179 million by BARDA for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic influenza. He has consulted on assay development, transfer, qualification and validation for monoclonal antibody and vaccine projects using VLP and virus vector platforms.